Ravoxertinib (GDC-0994) is an investigational small molecule inhibitor primarily studied for its potential in cancer therapy. It targets the MAPK signaling pathway, specifically inhibiting ERK1 and ERK2 kinases, which are often hyperactivated in various cancers due to mutations in upstream proteins like BRAF or RAS. By blocking ERK activity, ravoxertinib aims to suppress tumor cell proliferation and survival. It has been evaluated in clinical trials for advanced solid tumors, particularly those with specific genetic alterations such as KRAS or BRAF mutations, including non-small cell lung cancer and melanoma. Its development focuses on overcoming resistance to upstream inhibitors in the MAPK pathway, making it a candidate for use in combination therapies. For example, it has been studied alongside inhibitors of MEK or BRAF to enhance antitumor effects and delay resistance. Due to its targeted mechanism, ravoxertinib represents a strategy for precision oncology, aiming to deliver more effective treatment for patients with limited options due to resistant or aggressive disease.